Why AstraZeneca-Oxford potential COVID vaccine works better in low dose

They have claimed that the drug is 70.4 percent effective, and it makes a strong case for AstraZeneca#39;s India partner Serum Institute of India to seek licence for its potential vaccine, Covishield, in India.

from Moneycontrol Business News https://ift.tt/3nUdVHo